For the readers interested in the stock health of Atara Biotherapeutics Inc. (ATRA). It is currently valued at $4.72. When the transactions were called off in the previous session, Stock hit the highs of $4.785, after setting-off with the price of $4.16. Company’s stock value dipped to $4.105 during the trading on the day. When the trading was stopped its value was $4.16.Recently in News on January 13, 2023, Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 66,800 restricted stock units of Atara’s common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of Atara’s common stock to one such newly hired employee. These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of January 3, 2022, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4). You can read further details here
Atara Biotherapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.78 on 01/24/23, with the lowest value was $3.22 for the same time period, recorded on 01/04/23.
Atara Biotherapeutics Inc. (ATRA) full year performance was -66.26%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Atara Biotherapeutics Inc. shares are logging -71.13% during the 52-week period from high price, and 66.78% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.83 and $16.35.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1685150 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Atara Biotherapeutics Inc. (ATRA) recorded performance in the market was 43.90%, having the revenues showcasing 11.58% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 408.66M, as it employees total of 340 workers.
Market experts do have their say about Atara Biotherapeutics Inc. (ATRA)
During the last month, 4 analysts gave the Atara Biotherapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 2 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 4.08, with a change in the price was noted +0.76. In a similar fashion, Atara Biotherapeutics Inc. posted a movement of +19.19% for the period of last 100 days, recording 1,515,970 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ATRA is recording 0.02 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.02.
Technical breakdown of Atara Biotherapeutics Inc. (ATRA)
Raw Stochastic average of Atara Biotherapeutics Inc. in the period of last 50 days is set at 67.99%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 96.68%. In the last 20 days, the company’s Stochastic %K was 93.79% and its Stochastic %D was recorded 81.96%.
Bearing in mind the latest performance of Atara Biotherapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 43.90%. Additionally, trading for the stock in the period of the last six months notably improved by 48.90%, alongside a downfall of -66.26% for the period of the last 12 months. The shares increased approximately by 24.87% in the 7-day charts and went down by 42.60% in the period of the last 30 days. Common stock shares were driven by 11.58% during last recorded quarter.